Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 33 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

C-1999 Clofarabine, Free Base, >99%       Prices Reduced (March 2013)      NEW!

Synonyms:  [CAFdA] [Cl-F-Ara-A] [CHEBI:120185] [NSC-606869] [NSC 606869] [NSC606869]
Related Terms:  [Clofarex] [Clolar] [Evoltra]

M.W. 303.68

C10H11ClFN5O3

[123318-82-1]

M.I. 14:  2372

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 150 mg/mL; soluble in ethanol at 2.8 mg/mL with warming; soluble in water at 2.5 mg/mL with warming; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Clofarabine is a second generation purine nucleoside analogue.

• Clofarabine has multiple properties including inhibition of ribonucleotide reductase, incorporation into DNA, and induction of apoptosis.  Kantarjian, H.M., et al.  "Clofarabine:  past, present, and future."  Leuk. Lymphoma. 48:  1922-1930 (2007).

• When clofarabine was used in 42 pediatric patients with multiply relapsed or refractory acute myeloid leukemia (AML), the response rate was 26%, including one complete response without platelet recovery and 10 partial responses.  Jeha, S., et al.  "Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia."  J. Clin. Oncol. 27:  4392-4397 (2009).

• Clofarabine may be used in patients age 60 years or older with untreated AML who have at least one unfavorable prognostic factor.  Kantarjian, H.M., et al.  "Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors."  J. Clin. Oncol. 28:  549-555 (2010).

• Combination treatment of HCT-116, K562, HL-60, or RL tumors with clofarabine and 1-β-D-[4-thio-arabinofuranosyl]-cytosine (T-AraC) had dramatically superior anti-tumor activity than treatment with either agent alone, but this combination caused antagonism in CCRF-CEM tumors.  The antitumor activity of clofarabine plus T-AraC against HCT-116 tumors in vivo was much better than the activity observed with clofarabine plus 1-β-D-arabinofuranosyl cytosine (AraC).  Parker, W.B., et al.  "Enhancement of the in vivo antitumor activity of clofarabine by 1-β-D-[4-thio-arabinofuranosyl]-cytosine."  Cancer Chemother. Pharmacol. 64:  253-261 (2009).

• Clofarabine is a powerful radiosensitizer by interfering with the DNA damage response in vitro and in vivo.  Cariveau, M.J., et al.  "Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response."  Int. J. Radiat. Oncol. Biol. Phys. 70:  213-220 (2008).

• Clofarabine is the active ingredient in the drug product sold under the trade name Clolar® in the U.S. and Canada, and under the trade name Evoltra® in Europe and Australia/New Zealand.  This drug is currently approved in at least one country for use in children with relapsed or refractory acute lymphoblastic leukemia (ALL).  THE CLOFARABINE, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT CLOLAR® NOR EVOLTRA®, AND IS NOT FOR HUMAN USE.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.

** Our prices are lower than other vendors', but there is no compromise in quality.  Read how we are able to accomplish this:  Product Quality Discussion.

NOTES:
1.  The purpose of our competitor price comparison tables is to enable our visitors to compare the prices and purities of products of nominally equivalent quality, for vendors whose price and purity claims are openly available from a website or catalog (without a need for the customer to contact the vendor and request a quotation in order to obtain a price and purity for a standard product size).  However, the quality comparisons in these tables are not absolute:  although our product purities are uniformly very high and are established by careful testing of every lot in our laboratories, we cannot and do not vouch for the purities claimed by other vendors in these competitor price comparison tables.  (We do carry out occasional testing of other vendors' products -- see below --  and we have found many instances where vendors' product purities are far below their claimed levels.)  Effective April 1, 2011, our price comparison tables only include products where a purity commitment is found together with sizes and prices on at least one page of the vendor's web site.

2.  Researching and compiling sizes and prices for the >160 competitive vendors and more than 175 products is an expensive and tedious task for our small company.  Thus, we typically only perform revisions of these tables annually or less frequently.  The date and source of each competitive vendor's prices is indicated at the bottom of this page.  Obviously, we make no guarantee that competitive vendor prices will remain unchanged in the interval between our annual revisions.  We may occasionally update individual competitive vendor information and add new competitive vendors as we locate them.

3.  In some circumstances we permanently remove vendors from our price comparison tables.  Circumstances that lead to permanent removal are: 

A.  If a vendor does not honor its advertised price (ignoring small price increases) for one or more products when an order is attempted.  Example:  a vendor listed a compound at $808 for 10 grams on its website price list, but quoted $4,500 per 10 grams upon our inquiry.  That vendor has been permanently removed from our price comparison tables.

B.  If, on a product-by-product basis, our analyses of a vendor's product show purities more than a few percent below the vendor's advertised purities.  Example:  a vendor advertises a purity for 97% for a compound, but repeated elemental analyses show a minimum of 9% inorganic material present, beyond any salt counterion.  Another example: an HPLC analysis at a relevant UV detector wavelength shows 92% purity for a vendor's product for which 98% purity is claimed.  We realize of course that UV absorbances for impurities can be higher than for the main compound, but our products meet our purity commitment of typically >99% irrespective of absorbance factors for impurities, and we apply that standard to products from other vendors.

C.  Again on a product-by-product basis, if a vendor makes no purity claim for a given product, then their product is not shown on that product table.

D.  If we find that, as a pattern, several of a competitive vendor's products fail to meet their advertised purity commitments by significant margins or if a vendor does not provide standard and consistent purity claims for several of its products, then that vendor is permanently removed from all of our competitor price tables.

E.  Finally, if we determine that a vendor has provided fraudulent information on its website, in its literature or on a certificate of analysis, that vendor is permanently removed from all of our price comparison tables.

4.  IMPORTANT:  The presence of a competitive vendor entry in our price comparison tables does not necessarily mean that we have analyzed any of that vendor's products for purity; indeed, in most cases we have not.

5.  Please note:  where necessary, competitor prices are rounded to the nearest whole dollar.

To the best of our knowledge, the prices listed above for our competitors' products were correct as of the dates listed below for the sources of our annual price information update process.

Pricing Sources and Dates:  LC Labs - Current, Sigma-Aldrich - website - Jan 2013, Tocris Bioscience - website - Jan 2013, Santa Cruz Biotech - website - Jan 2013, BioVision - website - Mar 2013, D-L Chiral Chemicals - website - Jan 2013, PharmBlock - website - Apr 2013, R&D Systems - website - Jan 2013, AK Scientific - website - Mar 2013, TCI - website - Jan 2013, Alfa Aesar - website - Mar 2013, Carbone Scientific - website - Jan 2013, Medical Isotopes - website - Dec 2012, TCASChem Tech - website - Apr 2013, biorbyt.com - website - Jan 2013, Utech Products - website - Sep 2012, Acesobio - website - Jan 2013, ChemReagents.com - website - Jan 2013, P212121 - website - Jan 2013, AbMole BioScience - website - Dec 2012, MedKoo BioSciences - website - Apr 2013, Medchem Express - website - Jan 2013, AdooQ BioScience - website - Jan 2013, Krackeler Scientific - website - Jan 2013, ChemScene - website - Jan 2013.